Yurut-Caloglu V.Caloglu M.Kaplan M.Inci O.2024-06-122024-06-1220091513-7368https://hdl.handle.net/20.500.14551/17624Purpose: To evaluate prognostic factors affecting local control (LC), distant metastases-free survival (DMFS) and overall survival (OS) in bladder carcinoma patients undergoing extravesical extension. Patients and Methods: We retrospectively reviewed the charts of 61 consecutive patients with T3 or T4 bladder carcinoma, treated with definitive radiotherapy from 1999 through 2007. Results: Median age was 69 years and follow-up was 29 months. The LC rate was 33% at 4 years and was increased in patients with a Hb?12 g/dl (p=0.003) or a LDH<180 U/L (p=0.021) and in those who received concurrent chemotherapy (p=0.022) on univariate analysis. DMFS was affected by anemia (Hb<12 g/dl) (p=0.039), the absence of chemotherapy (p=0.034) and the presence of newlydiagnosed disease (p=0.01). The OS rate was 19% at 4 years. Non-pure transitional cell carcinoma histological type (p=0.024), anemia (p=0.004), elevated LDH (p=0.003), and newly diagnosed disease (p=0.011) were poor prognostic factors on univariate analyses for OS. Anemia was the only negative prognostic factor for LC (p=0.03), DMFS (p=0.002) and OS (p<0.0001) on multivariate analysis. Conclusion: Pre-treatment Hb level is the most important prognostic factor in patients treated with definitive radiotherapy, so that anemia may act as a surrogate biological marker for aggressive disease.eninfo:eu-repo/semantics/closedAccessAnemia; Bladder Cancer; Chemotherapy/Radiotherapy; Prognostic Factor; TurkeyHemoglobin; Adult; Aged; Article; Bladder Tumor; Blood; Cancer Invasion; Cancer Staging; Chi Square Distribution; Female; Human; Male; Middle Aged; Multimodality Cancer Therapy; Pathology; Prognosis; Proportional Hazards Model; Retrospective Study; Survival; Transitional Cell Carcinoma; Adult; Aged; Aged, 80 And Over; Carcinoma, Transitional Cell; Chi-Square Distribution; Combined Modality Therapy; Female; Hemoglobins; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Urinary Bladder NeoplasmsArticle106115111582-s2.0-7795662687720192602Q3